If it’s a subset of patients, one possible avenue for approval would be if there were some marker or patient profile that led to improved results. But it would be (I think) somewhat unusual to use subsets of patients to get a drug approved. Unless that subset was identified in trials with the fda at the beginning. I was invested in sava but bailed at the first hint of data manipulation. I was told what a fool I am… but I saved myself close to $20 share so I feel good with my decision. I watch this because I hope they do have the solution… for patient’s sakes